Donanemab vs Lecanemab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline
Donanemab · Kisunla
Marketed by Eli Lilly
NCT05108922 · Phase 3 · completed
Participants were randomized to donanemab or active-control aducanumab, but the trial was open-label rather than blinded. Both prespecified primary amyloid-clearance comparisons favored donanemab with statistically significant results; the biomarker-based primary endpoint and lack of blinding support a moderate evidence grade rather than a strong one.
Next expected readout: November 2027 · NCT05026866 (registry estimate)
Reported efficacy
Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on Donanemab Versus Aducanumab (6 Months); Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan in the Low/Medium (Intermediate) Subpopulation (Superiority) on Donanemab Versus Aducanumab (6 Months): Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on Donanemab Versus Aducanumab (6 Months): Donanemab 37.9% (95% CI 26.2 to 49.6) vs Aducanumab 1.6% (95% CI 0 to 4.6) (met)
Result source: NCT05108922
Lecanemab · Leqembi
Marketed by Eisai and partners
NCT01767311 · Phase 2 · completed
Randomized, triple-masked phase 2b in early Alzheimer's disease (856 participants). The Bayesian primary analysis of the ADCOMS composite at 12 months estimated a 63.8% posterior probability of meaningful benefit for the highest dose, short of the study's prespecified success criterion, so the primary endpoint was not met.
Next expected readout: December 2026 · NCT06602258 (registry estimate)
Reported efficacy
Core Study Phase: Change From Baseline in Alzheimer's Disease Composite Score (ADCOMS) at Month 12 (Core Study Phase: at Month 12); Core Study Phase: Number of Participants With All Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (From first dose of the study drug (Week 1) up to 90 days after last dose of study drug (up to 21 months)); OLE Phase: Number of Participants With All TEAEs and SAEs (From first dose of the study drug (Week 1) up to 30 days after last dose of study drug (up to 61 months)): ADCOMS change from baseline at Month 12 (lower = less decline): lecanemab 10 mg/kg biweekly 0.077 and 10 mg/kg monthly 0.084 vs placebo 0.113; lower doses did not separate: 2.5 mg/kg biweekly 0.134, 5 mg/kg monthly 0.119, 5 mg/kg biweekly 0.116. (missed)
Result source: NCT01767311
Results for Alzheimer's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Donanemab | Lecanemab |
|---|---|---|
| CDR-SB, change | 1.2 vs 1.6−0.4 vs placeboNCT03367403 | 1.2 vs 1.5−0.3 vs placeboNCT017673119 other results
|
| ADAS-Cog11, change | —Trial running · NCT06996730 | —Trial running · NCT01760005 |
| ADCS-ADL, change | —Trial running · NCT06996730 | —Trial running · NCT01760005 |
| MMSE, change | -2.4 vs -3.0+0.6 vs placeboNCT03367403 | —Trial running · NCT01760005 |
| Amyloid PET, change (centiloids) | -84.2 vs -72.2vs AducanumabNCT051089228 other results
| —Trial running · NCT01760005 |
CDR-SB, change
- Donanemab
- 1.2 vs 1.6−0.4 vs placeboNCT03367403
- Lecanemab
- 1.2 vs 1.5−0.3 vs placeboNCT01767311
9 other results
- 1.1 vs 1.5 NCT01767311
- 0.7 vs 0.9 NCT01767311
- 0.6 vs 0.9 NCT01767311
- 1.7 vs 1.5 NCT01767311
- 1.5 vs 1.5 NCT01767311
- 1.3 vs 0.9 NCT01767311
- 0.9 vs 0.9 NCT01767311
- 1.2 vs 1.5 NCT01767311
- 1.0 vs 0.9 NCT01767311
ADAS-Cog11, change
- Donanemab
- —Trial running · NCT06996730
- Lecanemab
- —Trial running · NCT01760005
ADCS-ADL, change
- Donanemab
- —Trial running · NCT06996730
- Lecanemab
- —Trial running · NCT01760005
MMSE, change
- Donanemab
- -2.4 vs -3.0+0.6 vs placeboNCT03367403
- Lecanemab
- —Trial running · NCT01760005
Amyloid PET, change (centiloids)
- Donanemab
- -84.2 vs -72.2vs AducanumabNCT05108922
8 other results
- -86.6 vs -72.2 NCT05108922
- -80.0 vs -56.1 NCT05108922
- -84.5 vs -57.8 NCT05108922
- -62.1 vs -16.4 NCT05108922
- -64.1 vs -23.8 NCT05108922
- -64.0 vs -56.1 NCT05108922
- -64.0 vs -56.1 NCT05108922
- -64.3 vs -72.2 NCT05108922
- Lecanemab
- —Trial running · NCT01760005
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Donanemab: 5 of 5 rows · Lecanemab: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Donanemab | Lecanemab |
|---|---|---|
| Brain Amyloid Change Centiloids absolute change · centiloids | -84.13 vs 0.93 placebo centiloids @ 76wka,b,c NCT03367403 · Phase 2 · registry result, not featured evidence · monotherapy | -72.495 vs 1.004 placebo centiloids @ 78wk10 mg/kg Biweeklyd,a,b,c NCT01767311 · Phase 2 show 4 more doses-53.412 vs 1.004 placebo centiloids @ 78wk10 mg/kg Monthly NCT01767311 · Phase 2 -46.217 vs 1.004 placebo centiloids @ 78wk5 mg/kg Biweekly NCT01767311 · Phase 2 -31.168 vs 1.004 placebo centiloids @ 78wk5 mg/kg Monthly NCT01767311 · Phase 2 -22.404 vs 1.004 placebo centiloids @ 78wk2.5 mg/kg Biweekly NCT01767311 · Phase 2 |
| Dropout rate | 21.6%e NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3 show 17 more results—Part B: Donanemab NCT04640077 · Phase 2 · registry result, not featured evidence —Period 2: Part B: Donanemab NCT04640077 · Phase 2 · registry result, not featured evidence 28.2%Donanemab Monotherapy (Donanemab-M NCT03367403 · Phase 2 · registry result, not featured evidence · monotherapy 20%Donanemab in Combination With LY32 NCT03367403 · Phase 2 · registry result, not featured evidence · combination 0%40 mg/kg SD NCT02624778 · Phase 1 · registry result, not featured evidence 14.3%20 mg/kg SD NCT02624778 · Phase 1 · registry result, not featured evidence 60%20 mg/kg Q4W NCT02624778 · Phase 1 · registry result, not featured evidence —10 mg/kg SD NCT02624778 · Phase 1 · registry result, not featured evidence 10%10 mg/kg Q2W NCT02624778 · Phase 1 · registry result, not featured evidence 50%10 mg/kg Q4W NCT02624778 · Phase 1 · registry result, not featured evidence 16.7%10 mg/kg IV NCT01837641 · Phase 1 · registry result, not featured evidence 18.2%3 mg/kg IV NCT01837641 · Phase 1 · registry result, not featured evidence 0%3 mg/kg SC NCT01837641 · Phase 1 · registry result, not featured evidence 11.1%1 mg/kg IV NCT01837641 · Phase 1 · registry result, not featured evidence 0%1 mg/kg IV NCT01837641 · Phase 1 · registry result, not featured evidence 0%0.3 mg/kg IV NCT01837641 · Phase 1 · registry result, not featured evidence 0%0.1 mg/kg / 0.3 mg/kg IV NCT01837641 · Phase 1 · registry result, not featured evidence | 46%10 mg/kg Biweeklyf NCT01767311 · Phase 2 show 5 more results38.7%10 mg/kg Monthly NCT01767311 · Phase 2 —10 mg/kg Biweekly NCT01767311 · Phase 2 33.7%5 mg/kg Biweekly NCT01767311 · Phase 2 27.5%5 mg/kg Monthly NCT01767311 · Phase 2 32.7%2.5 mg/kg Biweekly NCT01767311 · Phase 2 |
| Discontinued due to AEs | 4.1%e NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3 show 17 more results—Part B: Donanemab NCT04640077 · Phase 2 · registry result, not featured evidence —Period 2: Part B: Donanemab NCT04640077 · Phase 2 · registry result, not featured evidence 15.3%Donanemab Monotherapy (Donanemab-M NCT03367403 · Phase 2 · registry result, not featured evidence · monotherapy 13.3%Donanemab in Combination With LY32 NCT03367403 · Phase 2 · registry result, not featured evidence · combination 0%40 mg/kg SD NCT02624778 · Phase 1 · registry result, not featured evidence 0%20 mg/kg SD NCT02624778 · Phase 1 · registry result, not featured evidence 20%20 mg/kg Q4W NCT02624778 · Phase 1 · registry result, not featured evidence —10 mg/kg SD NCT02624778 · Phase 1 · registry result, not featured evidence 0%10 mg/kg Q2W NCT02624778 · Phase 1 · registry result, not featured evidence 0%10 mg/kg Q4W NCT02624778 · Phase 1 · registry result, not featured evidence 0%10 mg/kg IV NCT01837641 · Phase 1 · registry result, not featured evidence 9.1%3 mg/kg IV NCT01837641 · Phase 1 · registry result, not featured evidence 0%3 mg/kg SC NCT01837641 · Phase 1 · registry result, not featured evidence 0%1 mg/kg IV NCT01837641 · Phase 1 · registry result, not featured evidence 0%1 mg/kg IV NCT01837641 · Phase 1 · registry result, not featured evidence 0%0.3 mg/kg IV NCT01837641 · Phase 1 · registry result, not featured evidence 0%0.1 mg/kg / 0.3 mg/kg IV NCT01837641 · Phase 1 · registry result, not featured evidence | 7.5%10 mg/kg Biweeklyf NCT01767311 · Phase 2 show 5 more results9.1%10 mg/kg Monthly NCT01767311 · Phase 2 —10 mg/kg Biweekly NCT01767311 · Phase 2 5.4%5 mg/kg Biweekly NCT01767311 · Phase 2 3.9%5 mg/kg Monthly NCT01767311 · Phase 2 7.7%2.5 mg/kg Biweekly NCT01767311 · Phase 2 |
| Serious AEs | 18.3%e NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3 show 17 more results—Part B: Donanemab NCT04640077 · Phase 2 · registry result, not featured evidence 29.1%Period 2: Part B: Donanemab NCT04640077 · Phase 2 · registry result, not featured evidence 19.8%Donanemab Monotherapy (Donanemab-M NCT03367403 · Phase 2 · registry result, not featured evidence · monotherapy 20%Donanemab in Combination With LY32 NCT03367403 · Phase 2 · registry result, not featured evidence · combination 0%40 mg/kg SD NCT02624778 · Phase 1 · registry result, not featured evidence 0%20 mg/kg SD NCT02624778 · Phase 1 · registry result, not featured evidence 20%20 mg/kg Q4W NCT02624778 · Phase 1 · registry result, not featured evidence 0%10 mg/kg SD NCT02624778 · Phase 1 · registry result, not featured evidence 0%10 mg/kg Q2W NCT02624778 · Phase 1 · registry result, not featured evidence 12.5%10 mg/kg Q4W NCT02624778 · Phase 1 · registry result, not featured evidence 0%10 mg/kg IV NCT01837641 · Phase 1 · registry result, not featured evidence 0%3 mg/kg IV NCT01837641 · Phase 1 · registry result, not featured evidence 0%3 mg/kg SC NCT01837641 · Phase 1 · registry result, not featured evidence 11.1%1 mg/kg IV NCT01837641 · Phase 1 · registry result, not featured evidence 0%1 mg/kg IV NCT01837641 · Phase 1 · registry result, not featured evidence 28.6%0.3 mg/kg IV NCT01837641 · Phase 1 · registry result, not featured evidence 0%0.1 mg/kg / 0.3 mg/kg IV NCT01837641 · Phase 1 · registry result, not featured evidence | 15.5%10 mg/kg Biweeklyf NCT01767311 · Phase 2 show 5 more results12.3%10 mg/kg Monthly NCT01767311 · Phase 2 33.3%10 mg/kg Biweekly NCT01767311 · Phase 2 17.4%5 mg/kg Biweekly NCT01767311 · Phase 2 7.8%5 mg/kg Monthly NCT01767311 · Phase 2 19.2%2.5 mg/kg Biweekly NCT01767311 · Phase 2 |
| Most frequent reported AEs | e covid-19 28.2% amyloid related imaging abnormality-oedema/effusion 23.9% amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 18.3% NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3 show 16 more resultsamyloid related imaging abnormality-oedema/effusion 27.3% amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 18.2% infusion related reaction 14.5% NCT04640077 · Phase 2 · registry result, not featured evidence amyloid related imaging abnormality-oedema/effusion 25.2% (placebo 0.8%) fall 14.5% (placebo 16.8%) superficial siderosis of central nervous system 13.7% (placebo 3.2%) NCT03367403 · Phase 2 · registry result, not featured evidence · monotherapy amyloid related imaging abnormality-oedema/effusion 26.7% (placebo 0.8%) dizziness 26.7% (placebo 11.2%) arthralgia 20% (placebo 8%) NCT03367403 · Phase 2 · registry result, not featured evidence · combination 40 mg/kg SD vasogenic cerebral oedema 50% (placebo 0%) anxiety 25% (placebo 0%) post lumbar puncture syndrome 25% (placebo 0%) NCT02624778 · Phase 1 · registry result, not featured evidence 20 mg/kg SD headache 28.6% (placebo 0%) vasogenic cerebral oedema 28.6% (placebo 0%) asthenia 14.3% (placebo 0%) NCT02624778 · Phase 1 · registry result, not featured evidence 20 mg/kg Q4W cerebral microhaemorrhage 20% (placebo 0%) vasogenic cerebral oedema 20% (placebo 0%) arthralgia 10% (placebo 0%) NCT02624778 · Phase 1 · registry result, not featured evidence 10 mg/kg SD back pain 14.3% (placebo 0%) cellulitis 14.3% (placebo 0%) cerebral microhaemorrhage 14.3% (placebo 0%) NCT02624778 · Phase 1 · registry result, not featured evidence 10 mg/kg Q2W breast pain 25% (placebo 0%) cerebral microhaemorrhage 20% (placebo 0%) fatigue 20% (placebo 14.3%) NCT02624778 · Phase 1 · registry result, not featured evidence 10 mg/kg Q4W vasogenic cerebral oedema 37.5% (placebo 0%) anger 25% (placebo 0%) upper respiratory tract infection 25% (placebo 28.6%) NCT02624778 · Phase 1 · registry result, not featured evidence 10 mg/kg IV allergic sinusitis 16.7% (placebo 0%) bronchitis 16.7% (placebo 0%) ligament sprain 16.7% (placebo 0%) NCT01837641 · Phase 1 · registry result, not featured evidence 3 mg/kg IV infusion related reaction 27.3% (placebo 0%) fall 18.2% (placebo 0%) bursitis 9.1% (placebo 0%) NCT01837641 · Phase 1 · registry result, not featured evidence 3 mg/kg SC cerebral microhaemorrhage 12.5% (placebo 0%) fall 12.5% (placebo 0%) hypothyroidism 12.5% (placebo 0%) NCT01837641 · Phase 1 · registry result, not featured evidence 1 mg/kg IV infusion related reaction 22.2% (placebo 0%) arrhythmia 11.1% (placebo 0%) confusional state 11.1% (placebo 0%) NCT01837641 · Phase 1 · registry result, not featured evidence 1 mg/kg IV nausea 16.7% (placebo 0%) presyncope 16.7% (placebo 0%) upper respiratory tract infection 16.7% (placebo 8.3%) NCT01837641 · Phase 1 · registry result, not featured evidence 0.3 mg/kg IV cellulitis 14.3% (placebo 0%) diarrhoea 14.3% (placebo 0%) dizziness 14.3% (placebo 0%) NCT01837641 · Phase 1 · registry result, not featured evidence 0.1 mg/kg / 0.3 mg/kg IV apathy 25% (placebo 0%) arthralgia 25% (placebo 0%) chest discomfort 25% (placebo 0%) NCT01837641 · Phase 1 · registry result, not featured evidence | 10 mg/kg Biweeklyf infusion related reaction 19.3% (placebo 3.3%) headache 14.3% (placebo 10.2%) upper respiratory tract infection 11.8% (placebo 16.7%) NCT01767311 · Phase 2 show 5 more results10 mg/kg Monthly infusion related reaction 23.3% (placebo 3.3%) headache 17% (placebo 10.2%) urinary tract infection 9.9% (placebo 13.1%) NCT01767311 · Phase 2 10 mg/kg Biweekly fall 26.1% (placebo 11.4%) infusion related reaction 21.7% (placebo 3.3%) urinary tract infection 18.9% (placebo 13.1%) NCT01767311 · Phase 2 5 mg/kg Biweekly headache 18.5% (placebo 10.2%) urinary tract infection 18.5% (placebo 13.1%) fall 14.1% (placebo 11.4%) NCT01767311 · Phase 2 5 mg/kg Monthly cerebral microhaemorrhage 13.7% (placebo 4.9%) diarrhoea 13.7% (placebo 4.9%) nasopharyngitis 13.7% (placebo 11.4%) NCT01767311 · Phase 2 2.5 mg/kg Biweekly headache 17.3% (placebo 10.2%) upper respiratory tract infection 13.5% (placebo 16.7%) diarrhoea 9.6% (placebo 4.9%) NCT01767311 · Phase 2 |
Notes
- aPopulation context differs: registered conditions differ.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 76 weeks versus 78 weeks.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- ePopulation comparability has not been reviewed for 17 of these studies.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Donanemab
show 5 more results
show 8 more results
show 2 more results
+ 6 further endpoints in the CSV export.
Lecanemab
show 9 more results
show 9 more results
show 17 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Donanemab's landscape · Lecanemab's landscape